{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Liu J"],"funding":["Innovative Research Group Project of the National Natural Science Foundation of China","Xingliaoyingcaijihua Project of Liaoning Province","Natural Science Foundation of Liaoning Province","National Natural Science Foundation of China","China Postdoctoral Science Foundation"],"pagination":["14"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8796536"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(1)"],"pubmed_abstract":["Programmed cell death 1 ligand 1 (PD-L1) is the ligand for programmed death protein-1 (PD-1), is associated with immunosuppression. Signaling via PD-1/PD-L1 will transmits negative regulatory signals to T cells, inducing T-cell inhibition, reducing CD8<sup>+</sup> T-cell proliferation, or promoting T-cell apoptosis, which effectively reduces the immune response and leads to large-scale tumor growth. Accordingly, many antibody preparations targeting PD-1 or PD-L1 have been designed to block the binding of these two proteins and restore T-cell proliferation and cytotoxicity of T cells. However, these drugs are ineffective in clinical practice. Recently, numerous of studies have shown that, in addition to the surface of tumor cells, PD-L1 is also found on the surface of extracellular vesicles secreted by these cells. Extracellular vesicle PD-L1 can also interact with PD-1 on the surface of T cells, leading to immunosuppression, and has been proposed as a potential mechanism underlying PD-1/PD-L1-targeted drug resistance. Therefore, it is important to explore the production, regulation and tumor immunosuppression of PD-L1 on the surface of tumor cells and extracellular vesicles, as well as the potential clinical application of extracellular vesicle PD-L1 as tumor biomarkers and therapeutic targets. Video Abstract."],"journal":["Cell communication and signaling : CCS"],"pubmed_title":["Extracellular vesicle PD-L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies."],"pmcid":["PMC8796536"],"funding_grant_id":["2020M681016","81472302","XLYC1902050","2020-BS-103","82003040"],"pubmed_authors":["Peng X","Li X","Li H","Liu J","Zheng H","Yang L","He G","Wei S","Huang M","Zhang S","Fan Q","Yang S"],"additional_accession":[]},"is_claimable":false,"name":"Extracellular vesicle PD-L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies.","description":"Programmed cell death 1 ligand 1 (PD-L1) is the ligand for programmed death protein-1 (PD-1), is associated with immunosuppression. Signaling via PD-1/PD-L1 will transmits negative regulatory signals to T cells, inducing T-cell inhibition, reducing CD8<sup>+</sup> T-cell proliferation, or promoting T-cell apoptosis, which effectively reduces the immune response and leads to large-scale tumor growth. Accordingly, many antibody preparations targeting PD-1 or PD-L1 have been designed to block the binding of these two proteins and restore T-cell proliferation and cytotoxicity of T cells. However, these drugs are ineffective in clinical practice. Recently, numerous of studies have shown that, in addition to the surface of tumor cells, PD-L1 is also found on the surface of extracellular vesicles secreted by these cells. Extracellular vesicle PD-L1 can also interact with PD-1 on the surface of T cells, leading to immunosuppression, and has been proposed as a potential mechanism underlying PD-1/PD-L1-targeted drug resistance. Therefore, it is important to explore the production, regulation and tumor immunosuppression of PD-L1 on the surface of tumor cells and extracellular vesicles, as well as the potential clinical application of extracellular vesicle PD-L1 as tumor biomarkers and therapeutic targets. Video Abstract.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2026-06-19T03:08:01.417Z","creation":"2026-06-19T03:07:01.585Z"},"accession":"S-EPMC8796536","cross_references":{"pubmed":["35090497"],"doi":["10.1186/s12964-021-00816-w"]}}